An experimental study shows that adding a new drug to tirzepatide reduces muscle mass loss by half in obese patients. Participants lost the same amount of weight but retained more muscle. However, the trial is small, sponsored by the pharmaceutical company itself, and omits a key detail: the solution to the problem they created themselves comes with a patent price tag.
The Business of Programmed Weakness 💊
The industry knows that tirzepatide causes loss of lean mass, a known side effect not disclosed to consumers. Now, the new experimental compound promises to reverse it, creating a dependency package: one drug to lose weight and another to avoid becoming weak. The study, published in a restricted-access journal, does not compare its results with a high-protein diet and exercise, free options that do not generate recurring revenue.
Coming Soon to Your Pharmacy: The Monthly Strength Fee 💪
Soon you will be able to choose between losing weight and looking like a spaghetti noodle, or paying extra to keep your biceps. The home remedy, like eating lentils and getting off the couch, does not come in a lab presentation or a patented injection. But don't worry: if your muscle slips away, you can always buy the antidote. And if the antidote fails, they'll invent another one. The wheel of business never stops turning.